We are one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. We deliver innovative programs and services designed to increase the effectiveness and efficiency of the pharmaceutical supply chain in both human and animal health. Our new name represents a unified presence that will continue to fuel our ongoing growth strategy and advance our impact across healthcare. The U.S. healthcare solutions segment distributes a comprehensive offering of pharmaceuticals and related services to a wide variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, and other customers. Additionally, the U.S. healthcare solutions segment provides data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers, which reflects our commitment to operational flexibility and adaptability in response to market demands. Revenue increased by $23.6 billion, or 9.9%, from the prior fiscal year primarily due to revenue growth in our U.S. healthcare solutions segment, driven by unit volume growth and increased sales of specialty products. Our future revenue growth will continue to be affected by various factors, including industry growth trends, the introduction of new therapies, and changes in government rules and regulations. We recognize that our ability to respond effectively to environmental disruptions and transform ourselves to emerge stronger from challenging situations is critical to maintaining organizational resilience. The total increase in U.S. healthcare solutions revenues included significant increases in sales of products labeled for diabetes and/or weight loss, demonstrating our capacity to adapt to changing customer needs and market conditions. We experienced an increase in gross profit, favorably impacted by increases in both reportable segments, indicating our ability to maintain performance under pressure. Operating expenses increased primarily due to inflationary impacts and initiatives to improve operational efficiency across many of our businesses. Our operating income margin reflects our strategic response to market pressures and our commitment to maintaining organizational health and effectiveness. We are also focused on enhancing our operational management through technology initiatives and business transformation efforts, which are designed to improve our resilience against future disruptions. The cybersecurity event experienced by one of our foreign business units illustrates the importance of crisis management and preparedness in maintaining operational continuity. Our liquidity and capital resources have been sufficient to finance working capital and cash operating requirements, demonstrating our organizational strength and resourcefulness in navigating complex situations. We believe that our strategic planning and proactive measures will enable us to confront future challenges effectively, ensuring our long-term sustainability and success in a volatile market environment.